These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9721789)
1. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Krauss T; Augustin HG; Osmers R; Meden H; Unterhalt M; Kuhn W Obstet Gynecol; 1998 Sep; 92(3):457-60. PubMed ID: 9721789 [TBL] [Abstract][Full Text] [Related]
2. HELLP syndrome and factor V Leiden. Bozzo M; Carpani G; Leo L; Marcozzi S; Sacchi E; Moroni G; Pardi G Eur J Obstet Gynecol Reprod Biol; 2001 Mar; 95(1):55-8. PubMed ID: 11267721 [TBL] [Abstract][Full Text] [Related]
3. First-trimester repeated abortion is not associated with activated protein C resistance. Balasch J; Reverter JC; Fábregues F; Tàssies D; Rafel M; Creus M; Vanrell JA Hum Reprod; 1997 May; 12(5):1094-7. PubMed ID: 9194672 [TBL] [Abstract][Full Text] [Related]
4. Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. Muetze S; Leeners B; Ortlepp JR; Kuse S; Tag CG; Weiskirchen R; Gressner AM; Rudnik-Schoeneborn S; Zerres K; Rath W Acta Obstet Gynecol Scand; 2008; 87(6):635-42. PubMed ID: 18568463 [TBL] [Abstract][Full Text] [Related]
5. HELLP syndrome associated with factor V R506Q mutation. Brenner B; Lanir N; Thaler I Br J Haematol; 1996 Mar; 92(4):999-1001. PubMed ID: 8616100 [TBL] [Abstract][Full Text] [Related]
6. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Deschiens MA; Conard J; Horellou MH; Ameri A; Preter M; Chedru F; Samama MM; Bousser MG Stroke; 1996 Oct; 27(10):1724-30. PubMed ID: 8841318 [TBL] [Abstract][Full Text] [Related]
7. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856 [TBL] [Abstract][Full Text] [Related]
8. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. von Tempelhoff GF; Heilmann L; Spanuth E; Kunzmann E; Hommel G Thromb Res; 2000 Nov; 100(4):363-5. PubMed ID: 11187029 [No Abstract] [Full Text] [Related]
9. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Hallak M; Senderowicz J; Cassel A; Shapira C; Aghai E; Auslender R; Abramovici H Am J Obstet Gynecol; 1997 Apr; 176(4):889-93. PubMed ID: 9125617 [TBL] [Abstract][Full Text] [Related]
10. Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Sifontes MT; Nuss R; Hunger SP; Waters J; Jacobson LJ; Manco-Johnson M Am J Hematol; 1998 Jan; 57(1):29-32. PubMed ID: 9423813 [TBL] [Abstract][Full Text] [Related]
11. Frequency of hereditary thrombophilia, anticoagulant activity, and homocysteine levels in patients with hemolysis, elevated liver functions and low thrombocyte count (HELLP) syndrome. Dogan OO; Simsek Y; Celen S; Danisman N J Obstet Gynaecol Res; 2011 Jun; 37(6):527-33. PubMed ID: 21375667 [TBL] [Abstract][Full Text] [Related]
12. Prothrombin 20210 G: a mutation and Factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. van Pampus MG; Wolf H; Koopman MM; van den Ende A; Buller HR; Reitsma PH Hypertens Pregnancy; 2001; 20(3):291-8. PubMed ID: 12044337 [TBL] [Abstract][Full Text] [Related]
13. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Benedetto C; Marozio L; Salton L; Maulà V; Chieppa G; Massobrio M Acta Obstet Gynecol Scand; 2002 Dec; 81(12):1095-100. PubMed ID: 12519104 [TBL] [Abstract][Full Text] [Related]
14. ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome. Heilmann L; von Tempelhoff GF; Pollow K Clin Appl Thromb Hemost; 2002 Oct; 8(4):319-24. PubMed ID: 12518722 [TBL] [Abstract][Full Text] [Related]
15. Activated protein C resistance shows an association with pregnancy-induced hypertension. Horstkamp BS; Kiess H; Krämer J; Riess H; Henrich W; Dudenhausen JW Hum Reprod; 1999 Dec; 14(12):3112-5. PubMed ID: 10601105 [TBL] [Abstract][Full Text] [Related]
16. Effects of oral contraceptives on hemostasis and thrombosis. Rosing J; Tans G Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524 [TBL] [Abstract][Full Text] [Related]
17. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance. van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263 [TBL] [Abstract][Full Text] [Related]
18. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Schlembach D; Beinder E; Zingsem J; Wunsiedler U; Beckmann MW; Fischer T Clin Sci (Lond); 2003 Sep; 105(3):279-85. PubMed ID: 12725641 [TBL] [Abstract][Full Text] [Related]
19. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Price DT; Ridker PM Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368 [TBL] [Abstract][Full Text] [Related]
20. Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy. Ganzevoort W; Rep A; De Vries JI; Bonsel GJ; Wolf H; Hypertens Pregnancy; 2007; 26(4):433-45. PubMed ID: 18066962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]